Business Context and Reporting Period
This Form 8-K Current Report from Compass Therapeutics, Inc. (CMPX) covers the Annual Meeting of Stockholders held on June 13, 2024. The filing details the final voting results for matters submitted to shareholders, including the election of directors and the ratification of the independent auditor.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial metrics are disclosed in this document.
Material Changes
There are no material financial changes reported in this filing. The document solely reports the outcomes of shareholder votes compared to the proposals outlined in the definitive proxy statement filed on April 29, 2024.
Guidance, Outlook, and Management Commentary
The filing contains no management commentary, financial guidance, outlook, risks, or contingencies. It strictly reports the following voting outcomes:
- Proposal 1 (Election of Directors):
- Ellen V. Chiniara, J.D.: Elected with 76,766,213 votes For, 23,754,485 Withheld, and 17,705,143 Broker Non-votes.
- Mary Ann Gray, Ph.D.: Elected with 100,051,792 votes For, 468,906 Withheld, and 17,705,143 Broker Non-votes.
- Proposal 2 (Ratification of Auditor):
- CohnReznick, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- Votes: 118,180,952 For, 13,785 Against, 31,104 Abstained, and 0 Broker Non-votes.
Investor Verification Checklist
- Verify the full text of the definitive proxy statement (Form DEF 14A) filed on April 29, 2024, for detailed background on the director nominees and auditor appointment.
- Confirm the total number of shares outstanding and voting rights to contextualize the vote counts provided.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.